Faisal Mehmud, MD, MRCP is a seasoned pharmaceutical executive, who brings over 20 years of global experience as a senior medical professional in clinical development, medical affairs, and drug safety across various therapeutic areas, including oncology, hematology, rare diseases, and primary care. He has played a centralrole in multiple successful launches of new medicines and has spearheaded innovative global medical lifecycle management strategies including for small molecules, antibodies, cell therapies and cytotoxic chemotherapies. Dr. Mehmud's expertise encompasses late-phase development, product launch, and the seamless integration of new therapies into treatment pathways, all with a focus on improving patient outcomes through forward thinking clinical development plans. Dr. Mehmud’s career includes senior roles at leading pharmaceutical companies such as Sanofi, Novartis, Bristol Myers Squibb (BMS), Pfizer, and GlaxoSmithKline (GSK) based in London, Paris and Philadelphia. Most recently, Dr. Mehmud was the Senior Vice President, Data Generation and Scientific Communications in Worldwide Global Medical Affairs at GlaxoSmithKline (LSE/NYSE:GSK), which included leadership of medical affairs sponsored and supported,interventional and non-interventional clinical trials Before GSK, Dr. Mehmud was with Pfizer Inc. (NYSE: PFE), where he served in various roles including as Vice President and Worldwide Medical Franchise Head for Precision Medicine and Early Oncology Development, advancing the precision medicine oncology portfolio in a variety of tumor types, and supporting early-stage oncology projects moving from early clinical development to full development and market readiness, effectively bridging scientific innovation with commercial strategy. Dr. Mehmud has also held leadership roles at Bristol Myers Squibb(NYSE: BMY), including as Vice President in global drug safety, where he oversaw the safety risk management of complex therapies, including antibody-based treatments and cellular therapies. Dr. Mehmud completed a medical degree from the University of Cambridge, as well as diplomas in internal medicine and pharmaceutical medicine from the Royal College of Physicians and holds a medical license with the UK General Medical Council.
Andrew Smith
CFO
Andrew is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Andrew, until recently was the Chief Executive of SR Asset Management (SRAM) until its’ sale in 2024. Before joining SRAM in 2017, he was the Co-Head of Americas and Chief Operating Officer of Aberdeen Asset Management Inc. At Aberdeen, he held various roles including Chief Compliance Officer for their North American Closed End Funds as well as Chief Financial Officer and Chief Operating Officer for Aberdeen in the Americas. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. Andrew holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland.
Ruhena Chowdhury
Head of Clinical Operations
Ruhena is a clinical research professional with over 20 years’ experience in running clinical trials. Ruhena has worked on Phase 1-3 studies with small and large biopharma including Roche, AstraZeneca and Pfizer oncology studies covering 6 continents in H&N, oesophageal, liver, pancreatic, skin, lung and bladder cancers but also has experience of running non-oncology studies. Ruhena has worked in CROs and CDMOs giving her 360-degree experience on clinical programme management. Ruhena has a degree in Genetics and Microbiology from Queen Mary, University of London, DPhil in Cell and Molecular Biology from the University of Oxford and completed her Post-Doctoral training at Cancer Research UK where she made the transition from pre-clinical research to clinical trials project management successfully completing, at the time, the world’s largest NSCLC trial involving an IMP. Ruhena has keen interest in and specialises in precision medicine and biosample management.
Jens Bukrinski
Head of CMC
Jen’s is a CMC and Regulatory expert with 20+ years and 30+ drug development projects of which 8 are successfully approved and launched. He has been an independent CMC consultant since 2016 and is the founder of CMCAssist, Co-founder of Epoqe Pharma and former Novo Nordisk and Novozymes Biopharma.
Madison Weisz, MS
Biostatistics
Madison has experience across clinical development, biostatistics, and data analytics, with expertise in clinical study design and statistical analysis. Prior to joining Medicus Pharma, she held roles at Ocugen Inc. and the U.S. Chamber of Commerce Foundation, and has an MS in Applied Economics from George Washington University.
A Medicus Pharma Company
info@antev.co.uk
Antev, Ibex House, Baker Street
